ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,035.69
-1.57%
Dow Jones
37,815.92
0.00%
US Dollar vs MXN
17.08706
-0.38%
Brent Oil
84.875
-1.19%
Bitcoin
57,984.34
-4.31%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. AIM ImmunoTech Inc (AIM)

  7. AIM ImmunoTech Inc (AIM) Noticias

AIM AIM ImmunoTech Inc

0.4085
0.00 (0.00%)
Pre Mercado
Última actualización: 06:20:59
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
AIM ImmunoTech Inc AIM AMEX Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 0.4085 06:20:59
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.4085
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/4/202407:55GLOBEAIM ImmunoTech Announces First Dose Level is Generally..
25/4/202407:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
18/4/202407:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/4/202407:55GLOBEAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting..
11/4/202410:00GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
10/4/202407:21GLOBEAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned..
02/4/202406:30GLOBEAIM ImmunoTech Reports Fourth Quarter and Full Year 2023..
28/3/202407:05GLOBEAIM ImmunoTech to Present at the MedInvest Biotech & Pharma..
26/3/202408:05GLOBEAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023..
25/3/202408:05GLOBEAIM ImmunoTech Announces Publication of Positive Findings..
22/3/202407:55GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
20/3/202408:25GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/3/202407:45GLOBEAIM ImmunoTech to Participate in the Virtual Investor Lunch..
07/3/202407:45GLOBEAIM ImmunoTech Announces Launch of CEO Corner Platform
29/2/202407:45GLOBEAIM ImmunoTech Outlines Recent Progress Across Clinical..
21/2/202409:37EDGAR2Form D/A - Notice of Exempt Offering of Securities: [Amend]
20/2/202415:31EDGAR2Form 8-K - Current report
14/2/202407:55GLOBEAIM ImmunoTech Announces First Subject Dosed in the..
09/2/202414:47EDGAR2Form 8-K - Current report
08/2/202407:50GLOBEAIM ImmunoTech Reports Positive Topline Results from Phase 2..
25/1/202416:00EDGAR2Form 8-K - Current report
24/1/202408:10GLOBEAIM ImmunoTech Receives Erasmus Medical Center Ethics Board..
22/1/202407:55GLOBEAIM ImmunoTech Announces that the First Subject is Enrolled..
10/1/202412:42EDGAR2Form 8-K - Current report
10/1/202407:45EDGAR2Form 8-K - Current report
10/1/202407:45GLOBEAIM ImmunoTech Announces Open Enrollment for Phase 1b/2..
05/1/202412:32BWAIM Shareholders Elect All Four Company Director Nominees at..
03/1/202415:24EDGAR2Form SC 13D/A - General statement of acquisition of..
03/1/202415:24EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
03/1/202415:05PRNUSKellner Seeking Expedited Appeal of Delaware Court Finding..
29/12/202307:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/12/202307:00BWDelaware Court Rules in Favor of AIM ImmunoTech and Upholds..
28/11/202315:54EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/11/202315:30BWAIM ImmunoTech Provides Update Regarding Annual Meeting
27/11/202311:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202308:05GLOBEAIM ImmunoTech Bolsters Intellectual Property Estate for..
21/11/202311:00GLOBEAIM ImmunoTech Completes Treatment of Last Subject in Phase..
20/11/202316:29EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
20/11/202308:05EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
20/11/202306:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/11/202308:21EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
15/11/202306:30EDGAR2Form 8-K - Current report
15/11/202306:30GLOBEAIM ImmunoTech Reports Third Quarter 2023 Financial Results..
14/11/202309:00GLOBEAIM ImmunoTech Announces Publication of Data from Roswell..
09/11/202307:05GLOBEAIM ImmunoTech to Discuss Third Quarter 2023 Financial..
08/11/202315:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/11/202307:45EDGAR2Form 8-K - Current report
08/11/202307:45GLOBEAIM ImmunoTech Announces Encouraging Translational Data from..
07/11/202305:03EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/11/202308:25BWAIM ImmunoTech Files Definitive Proxy Statement and Sends..

Su Consulta Reciente

AMEX
AIM
AIM ImmunoTech
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados